Commentary: Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and QGut Model
暂无分享,去创建一个
K. Pang | E. Chow | K Sandy Pang | Edwin C Y Chow | E. Chow | K. S. Pang
[1] K. Pang,et al. Route-Dependent Metabolism of Morphine in the Vascularly Perfused Rat Small Intestine Preparation , 2000, Pharmaceutical Research.
[2] Sara K. Quinney,et al. Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin , 2010, Drug Metabolism and Disposition.
[3] Michael B. Bolger,et al. The composite solubility versus pH profile and its role in intestinal absorption prediction , 2008, AAPS PharmSci.
[4] M. Morris,et al. Formed and preformed metabolites: facts and comparisons , 2008, The Journal of pharmacy and pharmacology.
[5] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[6] Sara K Quinney,et al. Semiphysiologically Based Pharmacokinetic Models for the Inhibition of Midazolam Clearance by Diltiazem and Its Major Metabolite , 2009, Drug Metabolism and Disposition.
[7] K. Pang,et al. Presence of a diffusional barrier on metabolite kinetics: enalaprilat as a generated versus preformed metabolite. , 1986, Drug metabolism and disposition: the biological fate of chemicals.
[8] Baojian Wu. Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. , 2012, Journal of pharmaceutical sciences.
[9] J. Valentin. Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.
[10] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[11] S. Furlanetto,et al. Development and evaluation of an in vitro method for prediction of human drug absorption I. Assessment of artificial membrane composition. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[12] K. Pang,et al. 1α,25-Dihydroxyvitamin D3 Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Both fxr(−/−) and fxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo , 2011, Journal of Pharmacology and Experimental Therapeutics.
[13] Y. Sugiyama,et al. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[14] Michael B. Bolger,et al. Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine , 2009, The AAPS Journal.
[15] K. Pang,et al. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[16] K. Pang,et al. Why we need proper PBPK models to examine intestine and liver oral drug absorption. , 2012, Current drug metabolism.
[17] K. Pang,et al. Sequential first-pass elimination of a metabolite derived from a precursor , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[18] Y. Horsmans,et al. Differential induction of midazolam metabolism in the small intestine and liver by oral and intravenous dexamethasone pretreatment in rat , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[19] Qing-Yu Zhang,et al. Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse , 2011, Drug Metabolism and Disposition.
[20] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[21] K. Sandy Pang,et al. Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[22] Kin-Kai Hwang,et al. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. , 2002, European journal of medicinal chemistry.
[23] M. Fromm,et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin , 1996, Hepatology.
[24] N. Chalasani,et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts , 2001, Hepatology.
[25] A. Galetin,et al. Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. , 2010, Drug metabolism and pharmacokinetics.
[26] D. Shen,et al. Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.
[27] K. Pang,et al. Absorption of benzoic acid in segmental regions of the vascularly perfused rat small intestine preparation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[28] K. Pang,et al. Disparity in Intestine Disposition between Formed and Preformed Metabolites and Implications: A Theoretical Study , 2009, Drug Metabolism and Disposition.
[29] Harvey J. Clewell,et al. A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair , 2012, Drug Metabolism and Disposition.
[30] K. Pang,et al. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[31] Kenji Tabata,et al. Quantitative Prediction of Intestinal Metabolism in Humans from a Simplified Intestinal Availability Model and Empirical Scaling Factor , 2010, Drug Metabolism and Disposition.
[32] Qing-Yu Zhang,et al. The Role of Small-Intestinal P450 Enzymes in Protection against Systemic Exposure of Orally Administered Benzo[a]Pyrene , 2010, Journal of Pharmacology and Experimental Therapeutics.
[33] Malcolm Rowland,et al. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[34] D. Shen,et al. First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.
[35] R. Lledo-Garcia,et al. A Pharmacokinetic Model for Evaluating the Impact of Hepatic and Intestinal First-Pass Loss of Saquinavir in the Rat , 2011, Drug Metabolism and Disposition.
[36] K. Pang,et al. Effect of diffusional barriers on drug and metabolite kinetics. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[37] K. Pang,et al. Physiological Modeling to Understand the Impact of Enzymes and Transporters on Drug and Metabolite Data and Bioavailability Estimates , 2010, Pharmaceutical Research.
[38] Amir Heydari,et al. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA , 2006, Journal of psychopharmacology.
[39] A. Galetin,et al. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. , 2009, Journal of pharmaceutical sciences.
[40] Masoud Jamei,et al. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[41] H. Hirayama,et al. First-pass metabolism of salicylamide. Studies in the once-through vascularly perfused rat intestine-liver preparation. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[42] Jianghong Fan,et al. Interplay of transporters and enzymes in drug and metabolite processing. , 2009, Molecular pharmaceutics.
[43] K. Pang,et al. P-Glycoprotein and an Unstirred Water Layer Barring Digoxin Absorption in the Vascularly Perfused Rat Small Intestine Preparation: Induction Studies with Pregnenolone-16α-carbonitrile , 2006, Drug Metabolism and Disposition.
[44] Hong-Guang Xie,et al. Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats , 2010, Drug Metabolism and Disposition.
[45] Michael Gertz,et al. Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.
[46] P. Watkins,et al. The erythromycin breath test predicts the clearance of midazolam , 1995, Clinical pharmacology and therapeutics.
[47] Michael B Bolger,et al. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.
[48] K S Pang,et al. Disposition of enalapril in the perfused rat intestine-liver preparation: absorption, metabolism and first-pass effect. , 1985, The Journal of pharmacology and experimental therapeutics.
[49] K. Pang. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[50] Michael Gertz,et al. Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.
[51] T. Baillie,et al. Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.
[52] Jianghong Fan,et al. PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism. , 2010, Current drug metabolism.
[53] R. Kimura,et al. Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats , 2008, Drug Metabolism and Disposition.
[54] M. Pocard,et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.
[55] K. Pang,et al. Effect of flow on first-pass metabolism of drugs: single pass studies on 4-methylumbelliferone conjugation in the serially perfused rat intestine and liver preparations. , 1997, The Journal of pharmacology and experimental therapeutics.
[56] Y. Sugiyama,et al. Transport of Drugs Across the Hepatic Sinusoidal Membrane: Sinusoidal Drug Influx and Efflux in the Liver , 2000, Seminars in liver disease.
[57] P. Watkins,et al. Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans , 2002, Clinical pharmacology and therapeutics.